miR-200c modulates ovarian cancer cell metastasis potential by targeting zinc finger E-box-binding homeobox 2 (ZEB2) expression

This study was to investigate the effect of miR-200c on regulation of ovarian cancer cell metastasis potential and explore the underlying molecular events. qRT-PCR was used to analyze the level of miR-200c expression in 48 ovarian cancer and 30 normal ovarian tissue samples. pre-miR-200c was used to manipulate miR-200c expression in ovarian cancer cells for detection of changed phenotypes of tumor cells. Bioinformatics analysis was then used to predict target genes of miR-200c and GO and pathway analyses drew the miR-200c-related gene network. Luciferase reporter assay confirmed the target of miR-200c as ZEB2. Western blot was used to detect gene expressions in ovarian cancer cells. Level of miR-200c expression was much higher in ovarian cancer than in normal ovarian tissues, and miR-200c expression was inversely associated with advanced clinical stage and lymph node metastasis of ovarian cancer (p < 0.01). The database search predicted 186 miR-200c-targeting genes, and GO analysis showed that functions of these target genes were enriched in the protein binding and other biological processes. Furthermore, miR-200c expression inhibited ovarian cancer cell ES-2 migration and invasion capacity by suppression of ZEB2 expression (p < 0.01). Overexpression of miR-200c regulated E-cadherin and vimentin expression in ovarian cancer cells. This study demonstrated high miR-200c expression in ovarian cancer tissues and ZEB2 as a targeting gene of miR-200c, which mediated the effects of miR-200c on regulation of ovarian cancer cell migration and invasion capacity and epithelial-to-mesenchymal transition. Thus, targeting of miR-200c or ZEB2 may serve as a potential therapeutic strategy for control of ovarian cancer.

[1]  G. Berx,et al.  Evolutionary functional analysis and molecular regulation of the ZEB transcription factors , 2012, Cellular and Molecular Life Sciences.

[2]  G. Scambia,et al.  The epithelial-mesenchymal transition and the estrogen-signaling in ovarian cancer. , 2010, Current drug targets.

[3]  Scott Valastyan Retraction Note to: Roles of MicroRNAs and Other Non-coding RNAs in Breast Cancer Metastasis , 2012, Journal of Mammary Gland Biology and Neoplasia.

[4]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[5]  Zhihui Feng,et al.  A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. , 2009, Gynecologic oncology.

[6]  C. Croce,et al.  MicroRNA profiling in ovarian cancer. , 2013, Methods in molecular biology.

[7]  E. Berns,et al.  MicroRNAs in ovarian cancer biology and therapy resistance. , 2010, The international journal of biochemistry & cell biology.

[8]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[9]  Shuang-Di Li,et al.  Changes of miRNA-200c expression in ovarian cancer and its clinical significance: Changes of miRNA-200c expression in ovarian cancer and its clinical significance , 2011 .

[10]  P. Wimberger,et al.  microRNA and the pathogenesis of ovarian cancer – a new horizon for molecular diagnostics and treatment? , 2012, Clinical chemistry and laboratory medicine.

[11]  M. F. Shannon,et al.  A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. , 2008, Cancer research.

[12]  B. Karlan,et al.  Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. , 2010, Gynecologic oncology.

[13]  S. Spivack,et al.  Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. , 2007, Cancer research.

[14]  H. Katagiri,et al.  Mechanisms of Ovarian Cancer Metastasis: Biochemical Pathways , 2012, International journal of molecular sciences.

[15]  F. Kopp,et al.  miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression , 2012, PloS one.

[16]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[17]  S. Natsugoe,et al.  Epithelial–mesenchymal transition and mesenchymal–epithelial transition via regulation of ZEB‐1 and ZEB‐2 expression in pancreatic cancer , 2012, Journal of surgical oncology.

[18]  J. Gilabert-Estellés,et al.  Role of microRNAs in gynecological pathology. , 2012, Current medicinal chemistry.

[19]  Jae Hoon Kim,et al.  MicroRNA Expression Profiles in Serous Ovarian Carcinoma , 2008, Clinical Cancer Research.

[20]  Jun-qing Chen,et al.  Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer , 2012, Medical Oncology.

[21]  E. Howe,et al.  The miR-200 and miR-221/222 microRNA Families: Opposing Effects on Epithelial Identity , 2012, Journal of Mammary Gland Biology and Neoplasia.

[22]  M. Korpal,et al.  The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2* , 2008, Journal of Biological Chemistry.

[23]  G. Goodall,et al.  The microRNA-200 Family Regulates Epithelial to Mesenchymal Transition , 2008, TheScientificWorldJournal.

[24]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[25]  A. Rustgi,et al.  The role of the miR-200 family in epithelial-mesenchymal transition , 2010, Cancer biology & therapy.

[26]  Hong Zheng,et al.  Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer , 2013, Cancer biology & medicine.

[27]  Héctor Peinado,et al.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? , 2007, Nature Reviews Cancer.

[28]  A. Díaz-López,et al.  Cancer Management and Research Dovepress Role of Microrna in Epithelial to Mesenchymal Transition and Metastasis and Clinical Perspectives , 2022 .

[29]  C. Sourbier Ovarian cancer: emerging molecular-targeted therapies , 2012, Biologics : targets & therapy.

[30]  T. Brabletz,et al.  A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells , 2008, EMBO reports.

[31]  Dan Han,et al.  MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma , 2013, Tumor Biology.

[32]  Lionel L. A. In,et al.  MicroRNAs associated with tumour migration, invasion and angiogenic properties in A549 and SK-Lu1 human lung adenocarcinoma cells. , 2014, Lung cancer.

[33]  Michel Salzet,et al.  Epithelial-mesenchymal transition in ovarian cancer. , 2010, Cancer letters.

[34]  Alberto Izzotti,et al.  MicroRNAs in cancer treatment and prognosis. , 2012, American journal of cancer research.

[35]  Simone Brabletz,et al.  The ZEB/miR‐200 feedback loop—a motor of cellular plasticity in development and cancer? , 2010, EMBO reports.

[36]  R. Spizzo,et al.  Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. , 2013, Cancer discovery.